CRISPR Therapeutics

Crispr Therapeutics

Biotechnology, 828 Winter St, Boston, Massachusetts, 02451, United States, 201-500 Employees

crisprtx.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: 41*********

Who is CRISPR THERAPEUTICS

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas...

Read More

map

industries-icon Industry: Biotechnology

SIC SIC Code: 2836 | NAICS Code: 541715 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from CRISPR THERAPEUTICS

CRISPR Therapeutics Org Chart and Mapping

Employees

Jesse Hernandez

Manager Quality Operations

Rosemary Campbell

Senior Quality Control Specialist

Emily Huang

Research Associate, Bioanalytical Non-Viral Delivery

Mark Benton

Director, Clinical Development Scientist

Tarryn Simpson

Associate Director Human Resources

Catherine Ngo

Senior Manager Program Management

Melanie Allen

Senior Clinical Scientist

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding CRISPR Therapeutics

Answer: CRISPR Therapeutics's headquarters are located at 828 Winter St, Boston, Massachusetts, 02451, United States

Answer: CRISPR Therapeutics's phone number is 41*********

Answer: CRISPR Therapeutics's official website is https://crisprtx.com

Answer: CRISPR Therapeutics's revenue is $100 Million to $250 Million

Answer: CRISPR Therapeutics's SIC: 2836

Answer: CRISPR Therapeutics's NAICS: 541715

Answer: CRISPR Therapeutics has 201-500 employees

Answer: CRISPR Therapeutics is in Biotechnology

Answer: CRISPR Therapeutics contact info: Phone number: 41********* Website: https://crisprtx.com

Answer: CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access